Overview

Study With GW274150 In Patients With Mild Asthma

Status:
Completed

Trial end date:
2005-10-28

Target enrollment:
0

Participant gender:
All

Summary

This is a study investigating whether 14 days of dosing with GW274150 has a beneficial effect on a model of asthma type inflammation called the allergen-induced late asthmatic response. This will be compared with the response after treatment with a dummy (placebo) and a tablet treatment for asthma called Singulair (montelukast). Subjects in the study will receive all 3 treatments in a random order. The study is double-blind so subjects will not know which treatment they are taking at any given time.

Phase:

Phase 1

Accepts Healthy Volunteers?

Details

Lead Sponsor:

GlaxoSmithKline

Treatments:

Montelukast

Criteria

Inclusion criteria:

- Mild asthma: taking reliever medication (e.g. salbutamol) only.

- Screening involves measuring responses to the lung challenge agents: allergen, AMP,
and methacholine. Only those with specific types of response to these will be eligible
for the study.

Exclusion criteria:

- Recent steroid treatment.

- Significant illnesses or diseases other than asthma.